M&A / Deals Deep Science Ventures and MDC partner to accelerate brain treatments PharmaTimesNew collaboration aims to break barriers in braintargeted drug discoveryNeuroscienceRead full story pharminent June 2, 2026 (Last updated: June 4, 2026) PharmaTimes New collaboration aims to break barriers in braintargeted drug discovery Neuroscience Read full story Post navigation Previous: BMS secures FDA acceptance for Camzyos sNDANext: Abivax slides on phase 3 data in ulcerative colitis Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026